A Phase 3 interventional study of Idelalisib and Rituximab in Chronic Lymphocytic Leukemia, sponsored by Gilead Sciences. Completed at 72 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-14.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell — 1 open to participants now, 1 under way, none of them phase 3. idelalisib · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 6th largest by enrollment, is one of 5 that started in 2012, is one of 8 in phase 3, and was the 6th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →1 of the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell is open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Australia, Austria and 14 more countries
Ages 18+
By country, each count listing its studies:
idelalisib: first FDA approval 2014 (ZYDELIG), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 13 · Phase 3 8 · Phase 4 1
First in 2008; this study’s year is marked. 5 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 220 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 102 across the 25 interventional studies. Of the 22 that completed or were terminated, 21 (95%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 25 have an industry lead sponsor. The 7 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
36 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Gilead Sciences: none open now, none under way, none of them phase 3. Of 32 finished, 22 (69%) have results posted.
Among the 36 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Gilead Sciences, this one is the 8th largest by enrollment of the 35 interventional ones that give a count, is one of 7 that started in 2012, is one of 9 in phase 3, and was the 12th registered.
Gilead Sciences’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 36 in Leukemia, Lymphocytic, Chronic, B-Cell:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This Phase 3, randomized, double-blind, placebo-controlled study is to evaluate the effect of idelalisib in combination with rituximab on the onset, magnitude, and duration of tumor control in participants previously treated for chronic lymphocytic leukemia (CLL). Eligible patients will be randomized with a 1:1 ratio into 1 of the 2 treatment arms to receive either idelalisib plus rituximab or placebo plus rituximab. Participants who are tolerating primary study therapy but experience definitive CLL progression are eligible to receive active idelalisib therapy in the extension study, GS-US-312-0117.
Inclusion:
Participants will receive idelalisib plus rituximab
Drug: Idelalisib · Drug: Rituximab
Participants will receive placebo to match idelalisib plus rituximab
Drug: Rituximab · Drug: Placebo to match idelalisib
Idelalisib 150 mg tablet administered orally twice daily
Also known as: Zydelig®, GS-1101, CAL 101
Rituximab administered intravenously 8 times through Week 20: Day 1: 375 mg/m\^2, and 500 mg/m\^2 thereafter
Also known as: Rituxan®
Placebo to match idelalisib administered orally twice daily
Progression-Free Survival
Progression-free survival was defined as the interval from randomization to the earlier of the first documentation of definitive disease progression or death from any cause. Definitive disease progression was CLL progression based on standard criteria (other than lymphocytosis alone) as defined by the 2008 update of the International Workshop on CLL guidelines, ie, appearance of any new lesion; increase by ≥ 50% in the sum of the products of the perpendicular diameters of measured lymph nodes (SPD); new or ≥ 50% enlargement of liver or spleen; transformation to a more aggressive histology (eg, Richter's or prolymphocytic transformation); reduction in the number of blood cells (cytopenia) attributable to CLL.
Time frame: Up to 17 months
Overall Response Rate
Overall response rate was defined as the percentage of participants who achieved a best overall response of complete response or partial response. Complete response was defined as no lymphadenopathy, hepatomegaly, splenomegaly; normal complete blood count; confirmed by bone marrow aspirate \& biopsy. Partial response was defined as \>1 of the following criteria: a 50% decrease in peripheral blood lymphocytes, lymphadenopathy, liver size, spleen size; plus ≥ 1 of the following: ≥ 1500/μL absolute neutrophil count, \> 100000/μL platelets, \> 11.0 g/dL hemoglobin or 50% improvement for either of these parameters without transfusions or growth factors.
Time frame: Up to 17 months
Lymph Node Response Rate
Lymph node response rate was defined as the percentage of participants who achieved a ≥ 50% decrease from baseline in the SPD of index lymph nodes.
Time frame: Up to 17 months
Overall Survival
Overall survival was defined as the interval from randomization to death from any cause.
Time frame: Up to 17 months
Complete Response Rate
Complete response rate was defined as the percentage of participants who achieved a complete response.
Time frame: Up to 17 months
Participants were enrolled at a total of 53 study sites in the United States and Europe. The first participant was screened on 03 April 2012. The last study visit occurred on 20 April 2014.
| Milestone | Idelalisib + Rituximab | Placebo + Rituximab |
|---|---|---|
| Started | 110 | 110 |
| Completed | 87 | 97 |
| Not completed | 23 | 13 |
| Withdrew: Adverse event | 9 | 7 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Withdrawal by subject | 12 | 5 |
| Withdrew: Richter's transformation | 1 | 0 |
Progression-free survival was defined as the interval from randomization to the earlier of the first documentation of definitive disease progression or death from any cause. Definitive disease progression was CLL progression based on standard criteria (other than lymphocytosis alone) as defined by the 2008 update of the International Workshop on CLL guidelines, ie, appearance of any new lesion; increase by ≥ 50% in the sum of the products of the perpendicular diameters of measured lymph nodes (SPD); new or ≥ 50% enlargement of liver or spleen; transformation to a more aggressive histology (eg, Richter's or prolymphocytic transformation); reduction in the number of blood cells (cytopenia) attributable to CLL.
| months | Idelalisib + Rituximab | Placebo + Rituximab |
|---|---|---|
| Progression-Free Survival | NA (10.7 to NA) | 5.5 (3.8 to 7.1) |
Overall response rate was defined as the percentage of participants who achieved a best overall response of complete response or partial response. Complete response was defined as no lymphadenopathy, hepatomegaly, splenomegaly; normal complete blood count; confirmed by bone marrow aspirate \& biopsy. Partial response was defined as \>1 of the following criteria: a 50% decrease in peripheral blood lymphocytes, lymphadenopathy, liver size, spleen size; plus ≥ 1 of the following: ≥ 1500/μL absolute neutrophil count, \> 100000/μL platelets, \> 11.0 g/dL hemoglobin or 50% improvement for either of these parameters without transfusions or growth factors.
| percentage of participants | Idelalisib + Rituximab | Placebo + Rituximab |
|---|---|---|
| Overall Response Rate | 74.5 (65.4 to 82.4) | 14.5 (8.5 to 22.5) |
Lymph node response rate was defined as the percentage of participants who achieved a ≥ 50% decrease from baseline in the SPD of index lymph nodes.
| percentage of participants | Idelalisib + Rituximab | Placebo + Rituximab |
|---|---|---|
| Lymph Node Response Rate | 92.2 (85.1 to 96.6) | 5.9 (2.2 to 12.5) |
Overall survival was defined as the interval from randomization to death from any cause.
| months | Idelalisib + Rituximab | Placebo + Rituximab |
|---|---|---|
| Overall Survival | NA (NA to NA) | NA (12.8 to NA) |
Complete response rate was defined as the percentage of participants who achieved a complete response.
| percentage of participants | Idelalisib + Rituximab | Placebo + Rituximab |
|---|---|---|
| Complete Response Rate | 0 | 0 |
Collected over During study treatment plus 30 days (up to 2 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Idelalisib + Rituximab | — | 65/110 (59.1%) | 103/110 (93.6%) |
| Placebo + Rituximab | — | 43/108 (39.8%) | 102/108 (94.4%) |
| Event | Idelalisib + Rituximab | Placebo + Rituximab |
|---|---|---|
| PneumoniaInfections and infestations | 13/110 | 10/108 |
| PyrexiaGeneral disorders | 10/110 | 3/108 |
| DiarrhoeaGastrointestinal disorders | 8/110 | 0/108 |
| SepsisInfections and infestations | 7/110 | 3/108 |
| Febrile neutropeniaBlood and lymphatic system disorders | 5/110 | 6/108 |
| CellulitisInfections and infestations | 1/110 | 4/108 |
| ColitisGastrointestinal disorders | 4/110 | 0/108 |
| Pneumocystis jirovecii pneumoniaInfections and infestations | 4/110 | 1/108 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 4/110 | 1/108 |
| AstheniaGeneral disorders | 2/110 | 3/108 |
| Event | Idelalisib + Rituximab | Placebo + Rituximab |
|---|---|---|
| PyrexiaGeneral disorders | 40/110 | 18/108 |
| FatigueGeneral disorders | 34/110 | 35/108 |
| CoughRespiratory, thoracic and mediastinal disorders | 27/110 | 34/108 |
| Infusion related reactionInjury, poisoning and procedural complications | 21/110 | 33/108 |
| DiarrhoeaGastrointestinal disorders | 31/110 | 19/108 |
| NauseaGastrointestinal disorders | 30/110 | 25/108 |
| NeutropeniaBlood and lymphatic system disorders | 28/110 | 21/108 |
| ChillsGeneral disorders | 27/110 | 16/108 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 17/110 | 22/108 |
| Decreased appetiteMetabolism and nutrition disorders | 18/110 | 12/108 |
ITT Analysis Set: randomized participants with treatment group designated according to initial randomization.
| Age, Continuous(years) | Idelalisib + Rituximab | Placebo + Rituximab | Total |
|---|---|---|---|
| Mean | 71 ± 7.7 | 70 ± 8.1 | 71 ± 7.9 |
| Age, Customized(participants) | Idelalisib + Rituximab | Placebo + Rituximab | Total |
|---|---|---|---|
| < 65 years | 21 | 27 | 48 |
| ≥ 65 years | 89 | 83 | 172 |
| Sex: Female, Male(Participants) | Idelalisib + Rituximab | Placebo + Rituximab | Total |
|---|---|---|---|
| Female | 34 | 42 | 76 |
| Male | 76 | 68 | 144 |
| Race/Ethnicity, Customized(participants) | Idelalisib + Rituximab | Placebo + Rituximab | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 5 |
| Not Hispanic or Latino | 101 | 102 | 203 |
| Not Permitted | 6 | 6 | 12 |
| Race/Ethnicity, Customized(participants) | Idelalisib + Rituximab | Placebo + Rituximab | Total |
|---|---|---|---|
| White | 100 | 98 | 198 |
| Black or African American | 3 | 3 | 6 |
| Other | 2 | 2 | 4 |
| Not Permitted | 5 | 7 | 12 |
| Region of Enrollment(participants) | Idelalisib + Rituximab | Placebo + Rituximab | Total |
|---|---|---|---|
| France | 3 | 3 | 6 |
| Germany | 7 | 5 | 12 |
| Italy | 2 | 5 | 7 |
| United Kingdom | 18 | 14 | 32 |
| United States | 80 | 83 | 163 |
| Karnofsky Performance Status(participants) | Idelalisib + Rituximab | Placebo + Rituximab | Total |
|---|---|---|---|
| 40 | 1 | 1 | 2 |
| 50 | 3 | 4 | 7 |
| 60 | 6 | 5 | 11 |
| 70 | 20 | 13 | 33 |
| 80 | 42 | 46 | 88 |
| 90 | 23 | 28 | 51 |
| 100 | 15 | 13 | 28 |
| Time Since Diagnosis(months) | Idelalisib + Rituximab | Placebo + Rituximab | Total |
|---|---|---|---|
| Mean | 108.3 ± 62.28 | 106.4 ± 52.73 | 107.4 ± 57.58 |
2 further baseline measures are reported on the registry.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
The record gives a start of Apr 2012, a primary completion of Oct 2013 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Idelalisib
Leukemia, Lymphocytic, Chronic, B-Cell →